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SIONS: With the exception of ﬂuoxetine, our sample of
NF residents showed that weight gains with mirtazapine
were not statistically different from other non-TCA 
antidepressants once factors such as baseline weight,
gender, dose and co-morbid diagnoses are controlled for 
statistically.
PMH6
EVALUATING THE EFFECTIVENESS OF
FLUOXETINE 90MG ADMINISTERED EVERY
WEEK AND EVERY 2 WEEKS IN NURSING HOME
RESIDENTS
Bellnier T, Karki S, Ortega T, Decatur A
School of Pharmacy, SUNY at Buffalo, Rochester, NY, USA
OBJECTIVE: To evaluate the effectiveness of ﬂuoxetine
90mg every week/every 2 weeks in elderly nursing home
residents. METHOD: Twenty patients were randomly
selected who had been stabilized on 20mg ﬂuoxetine
daily for 3 months were switched to ﬂuoxetine 90mg
every week. An additional 20 patients were randomly
selected who had been stabilized on 10mg ﬂuoxetine
daily for 3 months and switched to ﬂuoxetine 90mg every
2 weeks. The Geriutric Depression Scale (GDS) was
administered to all patients to assess effectiveness one
week before and six weeks after the switch. Costs were
calculated as drug acquisition cost, nursing time, and
pharmacy time. Generic ﬂuoxetine was used in both cases
for 3 months prior to switching to ﬂuoxetine 90mg
weekly. RESULTS: Subject Characteristics: Fluoxetine
Weekly Group/Fluoxetine Every 2 Week Group Respec-
tively: Age: 81 + 8/82 + 9, Sex: 14 females/8 females, Eth-
nicity: 6% AA, 1% Hispanic/7% AA, 1% Hispanic.
Effectiveness: There was no statistically signiﬁcant differ-
ence in GDS scores before or after the switch for either
the ﬂuoxetine 90mg weekly group or the ﬂuoxetine 90
mg every 2 weeks group. Costs: Costs ($) for a 2-week
period before and after the switch were as follows: Flu-
oxetine 90mg Weekly Before/After Respectively: Drug
acquisition costs—1.68/33.38, Nursing costs—21.00/
3.00, Pharmacy costs—23.38/3.34, Total—46.06/39.72,
P > 0.05. Fluoxetine 90mg every 2 weeks Before/After
Respectively: Drug acquisition costs—0.84/16.69,
Nursing costs—21.00/1.50, Pharmacy costs—23.38/
3.34, Total—45.22/19.03, P < .05. CONCLUSION: This
suggests that ﬂuoxetine 90mg weekly and ﬂuoxetine 90
mg every 2 weeks are effective in nursing home patients.
The costs associated with the administration of medica-
tion may be a more signiﬁcant factor to consider when
evaluating cost effectiveness. Our ﬁndings are limited by
the small sample size and did not account for other costs
due to adverse effects, noncompliance, and medication
errors.
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A MARKOV COHORT SIMULATION ESTIMATING
THE RISK OF DEVELOPING CORONARY HEART
DISEASE IN PATIENTS USING ANTIPSYCHOTIC
DRUGS
Tahami Monfared AA1, Gueylard Chenevier D1,
Lescrauwaet B2, LeLorier J1
1Centre Hospitalier de l’Université de Montréal, Campus
Hôtel Dieu, Montreal, QC, Canada; 2Pﬁzer Canada Inc,
Kirkland, QC, Canada
OBJECTIVES: Atypical antipsychotic (AAP) drugs are
recommended as a ﬁrst-line pharmacotherapeutic strat-
egy for schizophrenia. Although these drugs offer an
improved neurological side-effect proﬁle, they can be
associated with important weight gain, increased serum
triglyceride levels, glucose intolerance, and diabetes 
mellitus. Clustering of these effects is associated with the
metabolic syndrome, which can greatly increase the risk
of coronary heart disease (CHD). The objective of this
study was to examine the impact of metabolic induced
changes by AAPs on the development of CHD in schizo-
phrenic patients. METHODS: A Markov model was 
constructed using disease state probabilities derived 
from published PROCAM logistic regression model and
published literature to link risk factors to disease inci-
dence in order to estimate the risk of developing CHD.
Based on the presence or absence of potential CHD risk
factors, persons were assigned transition probabilities 
of remaining in good health or moving into develop-
ing CHD (absorbing phase). The main outcome of the 
study was the risk of developing CHD in a hypothetical
cohort, and in turn, to estimate the proportion remaining
disease-free. RESULTS: The relative risk of CHD associ-
ated with triglyceride level and obesity was examined.
Clustering of these two metabolic effects, seen in patients
treated with certain AAPs, is associated with a two-fold
increased risk of CHD in men. The model generated real-
istic results, which are in total agreement with previously
published literature. CONCLUSIONS: This model can be
used as an effective instrument for assisting in the care of
persons at high risk of CHD. Moreover, it can be used to
estimate the impact of AAP induced metabolic changes
on the risk of CHD in individual patients. Physicians can
also use this tool to assess the beneﬁt/risk ratio of patients
that respond well to AAPs but develop metabolic side
effects.
PMH8
PHARMACOLOGIC TREATMENT OF
HOSPITALIZED PATIENTS WITH 
BIPOLAR DISORDER
Gaylord B1, Zhao Z2, Wang PF1, Gutierrez B1
1Premier, Inc, Charlotte, NC, USA; 2Eli Lilly and Company,
Indianapolis, IN, USA
Objective: To assess recent pharmacologic treatment pat-
terns for hospitalized bipolar patients. METHODS: Using
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Premier’s PerspectiveTM database, the largest U.S. 
hospital drug utilization database, hospitalized bipolar
patients discharged between January 1999 and Septem-
ber 2001 were identiﬁed. Psychotropic treatment patterns
and their relationship with diagnoses, illness severity, 
and patient and institution characteristics were analyzed.
RESULTS: Of 36,339 patients (61% female, mean age
39.7 years), 28.9% were depressed, 21.6% manic, 21.0%
mixed, and 28.5% other episodes. Valproate (45.9%) 
and olanzapine (30.2%) were most commonly prescribed
(Lithium, 24.9%). On average, patients received 3.87
psychotropics; 77.1% received 3 and 32.5% received 5.
Only 7.2% received monotherapy. Antipsychotic + mood
stabilizer combinations were used by 58.0%. Mood 
stabilizers or antipsychotics alone combined with other
classes were used by 23.1% and 12.6% of patients,
respectively. Among depressed patients, 79.1% used anti-
depressants versus 25.5% of manic patients. In depressed
patients with psychosis, 74.5% received atypicals versus
42.8% of patients without psychosis. However, 61.5% 
of depressed patients received anxiolytics and 24.5%
received hypnotics. Olanzapine use increased, and risperi-
done, valproate, and lithium use decreased from
1999–2001. Female, greater severity, and depressed/
mixed diagnosis increased pharmacotherapy complexity.
CONCLUSIONS: Pharmacotherapy for hospitalized
bipolar patients is complex. Combinations of 3 psy-
chotropics were dominant treatment regimens.
PMH9
INFLUENCE OF PHYSICIAN MIX AND SUPPLY
ON THE DIFFUSION OF ATYPICAL
ANTIPSYCHOTIC AGENTS
Shetty SS, Brooks JM
University of Iowa, Iowa City, IA, USA
OBJECTIVES: The objectives of this study are to estimate
the diffusion curve of atypical antipsychotic agents and
to investigate the inﬂuence of physician mix and supply
on the diffusion cycle. METHODS: Retrospective analy-
sis of Iowa Medicaid pharmacy claims data were done for
the period January 1990 till June 2000 to identify the per-
centage of patients receiving atypical agents in each
county and each month. Antipsychotic agents were iden-
tiﬁed using the National Drug Codes for antipsychotic
agents. Information on physicians practicing in each
county was obtained from the Iowa Physician Database.
To test whether the diffusion cycle follows the S-shaped
curve, a cubic regression model was run where the depen-
dent variable is percentage of patients receiving atypical
agents in each month and the independent variable is
time. The effect of physician factors were tested using
weighted multiple regression analysis where each inde-
pendent variable was interacted with time, time2 and
time3. RESULTS: The number of observations to test the
shape of the diffusion curve is 126 (state aggregate over
sample period) and the number of observations to test the
inﬂuence of physician mix and supply is 12,474 (99 coun-
ties over sample period). The results revealed that time
and time3 were negatively signiﬁcant and time2 was pos-
itively signiﬁcant suggesting that the diffusion curve
resembles the S-shaped curve. Diffusion of atypical agents
accelerated earlier in counties having higher number 
of physicians. Diffusion accelerated faster in counties 
having higher percentage of high network physicians 
and counties having higher percentage of younger physi-
cians. Information available was not sufﬁcient to indicate
that high psychiatrist counties had a faster diffusion of
atypical agents. CONCLUSIONS: Physician mix and
supply factors affected differently at different phases of
the diffusion cycle. Understanding the role of physician
mix and supply on uneven diffusion will help the 
policy makers develop interventions to take care of this
disparity.
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ETHNICITY AND SCHIZOPHRENIA
MEDICATION CHOICE: HALOPERIDOL,
RISPERIDONE, OR OLANZAPINE
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OBJECTIVES: Research has shown that patients with
schizophrenia may respond better to 2nd generation
antipsychotics versus older antipsychotics due to superior
efﬁcacy and safety proﬁles. However, reduced likelihood
of ethnic minorities receiving newer antipsychotics may
be associated with reduced medication adherence and
health service utilization, potentially contributing to poor
response rates. The purpose of this study was to examine
if ethnicity helped predict whether patients with schizo-
phrenia were prescribed 1) haloperidol versus risperidone
or olanzapine, and 2) risperidone versus olanzapine,
when controlling for other factors. METHODS: Texas
Medicaid claims were analyzed for persons, age 21 to 65,
diagnosed with schizophrenia or schizoaffective disorder,
initiating treatment with olanzapine (N = 1875), risperi-
done (N = 982), or haloperidol (N = 726) between
January 1997 and August 1998. The association between
antipsychotic prescribing and ethnicity (African Ameri-
can, Mexican American, or Caucasian) was assessed
using logistic regression. Covariates included other
patient demographics, region, comorbid mental health
conditions, and prior medication and health care resource
use. RESULTS: The results of the haloperidol versus
risperidone or olanzapine analysis indicated that African
Americans were signiﬁcantly less likely than Caucasians
to receive 2nd generation antipsychotics (OR = 0.657;
95% CI: 0.539, 0.801; p < 0.001). Ethnicity was not asso-
ciated with signiﬁcant differences in the use of risperidone
versus olanzapine. CONCLUSIONS: When other factors
were controlled, African Americans were signiﬁcantly less
likely to receive the newer antipsychotics. Among those
who did receive the newer antipsychotics, ethnicity did
not affect medication choice.
